Compare ARK Genomic Revolution ETF (ARKG) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Las Vegas Sands Corp. — how do they compare? ARK Genomic Revolution ETF trades at $44.61, while Las Vegas Sands Corp. trades at $45.48 (market cap $29.44B). The key difference: Las Vegas Sands Corp. pays a 2.64% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Las Vegas Sands Corp. nearer its low. Which is the better fit depends on your goals.
| ARKG | LVS | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $44.55 | $69.49 |
52-Week Low | $24.02 | $44.78 |
Market Cap | — | $29.44B |
Enterprise Value | — | $41.33B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $44.69 with a 0.86% daily gain, showing bullish momentum with strong moving average signals but overbought oscillators. The ETF focuses on genomic revolution companies with 59% concentration in top 10 holdings and long-term EPS growth of 10.7%. Recent news highlights biotech sector strength and ARKG's recovery from July correction.
Outlook remains positive given biotech sector tailwinds including FDA friendliness and AI-driven drug discovery, though high RSI readings suggest near-term caution. Key risks include sector volatility and concentrated portfolio exposure.
LVS trades at $45.75, up 0.64% over the past 24 hours, with a bearish technical signal but strong fundamentals including a P/E of 17.62 and net income margin of 12.59%. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company maintains robust cash flow from operations at $3.02 billion in 2025 and has announced a $0.30 dividend for H2 2026, reflecting financial stability.
The outlook for LVS is cautiously optimistic, supported by analyst consensus price target of $60.75 and 59% buy ratings. Key opportunities include revenue growth and ESG achievements, while risks involve high debt levels and competitive pressures in the gaming sector. Investors should weigh solid profitability against macroeconomic and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
